ASCO 2026: Known for its leadership in antibody-drug conjugates, Daiichi Sankyo's US CEO and new Head of Global R&D discuss ASCO data and investments it will be making throughout oncology

8 minutes ago
1 min read

Ken Keller and John Tsai describe which other modalities besides ADCs that Daiichi thinks about, and cover ASCO and pipeline progress on Enhertu (Her2), Datroway (Trop2), the company's B7-H3.

Recent Posts

See All

$ASCO 2026: Aulos Bioscience presented updated phase 2 data in checkpoint inhibitor-refractory metastatic melanoma for its IL-2 redirecting antibody, imneskibart$

ASCO 2026: Aulos Bioscience presented updated phase 2 data in checkpoint inhibitor-refractory metastatic melanoma for its IL-2 redirecting antibody, imneskibart

ASCO 2026: BeOne Medicines presented at this year's meeting long-term data on Brukinsa in CLL and combo data with the company's Bcl-2. Chairman & CEO John V. Oyler discusses that and new modalities

ASCO 2026: Allogene announced a CEO succession plan late last week. The two leaders behind it discuss why now is the right time, and update us on the progress of the company's programs

ASCO 2026: Known for its leadership in antibody-drug conjugates, Daiichi Sankyo's US CEO and new Head of Global R&D discuss ASCO data and investments it will be making throughout oncology

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight